Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZDTYD)

Drug Name

Bezuclastinib Drug Info

Synonyms

Bezuclastinib; CGT9486; PLX-9486; 2ROQ545LAG; PLX9486; CGT-9486; 1616385-51-3; UNII-2ROQ545LAG; PLX 9486 [WHO-DD]; 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide; 3,4-Dimethyl-N-(2-phenyl-1H-pyrrolo(2,3-b)pyridin-5-yl)-1H-pyrazole-5-carboxamide; 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide; Bezuclastinib [WHO-DD]; BEZUCLASTINIB [INN]; BEZUCLASTINIB [USAN]; CHEMBL5095229; SCHEMBL15824576; GTPL11868; NVSHVYGIYPBTEZ-UHFFFAOYSA-N; BDBM392363; GLXC-26827; EX-A5975; US10301280, Compound P-2007; US10301280, Compound P-2164; MS-24986; HY-145557; CS-0376032; 1H-Pyrazole-3-carboxamide, 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-; 3,4-dimethyl-N-(2-phenyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazole-5-carboxamide; WEJ

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal stromal tumour	2B5B	Phase 3	[1]

Cross-matching ID

PubChem CID: 75593308
TTD Drug ID: DMZDTYD

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
KIT D816V mutant (KIT D816V)	TTGTJB2	KIT_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05208047) A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Cogent Biosciences